Genotropin: price, description and usage
Genotropin is a recombinant human growth hormone (also called somatropin). It has the same structure as natural human growth hormone which is needed for muscles to grow. It also helps your fat and muscle tissues to develop in the right amounts. It is recombinant meaning it is not made from human or animal tissue. Somatropin is produced by a method known as ‘recombinant DNA technology’. It is made by an organism that has received a gene (DNA), which makes it able to produce growth hormone.
Genotropin is identical to the growth hormone that human body makes. This means you can feel confident and making safe, without side effects growth hormone therapy.
|HGH Genotropin price|
|1 pen - 12 mg / 36 IU/||€ 195|
|5 pens||€ 900|
Other names: somatropin, somatotropin
Genotropin - benefits for bodybuilders and fitness competitors!
Except for the treatment of children and adults with reduced growth hormone production, Genotropin is used by bodybuilders and fitness competitors! They may experience the following benefits:
- Increases of pure muscle mass.
- Increases protein synthesis.
- Increases Muscle Strength.
- Increases of muscle stamina.
- Reduces subcutaneous fat.
- Better condition of joints and tendons.
- Improved condition of the skin.
- Healthier hair and nails.
- Better Sleep
- Best anti age product.
1. HGH Genotropin: Clinical pharmacology
1.1 Mechanism of Action
Somatropin (as well as endogenous HGH) binds to a dimeric GH receptor in the cell membrane of target cells resulting in intracellular signal transduction and a host of pharma- codynamic effects. Some of these pharmacodynamic effects are primarily mediated by IGF-I produced in the liver and also locally (e.g., skeletal growth, protein synthesis), while others are primarily a consequence of the direct effects of somatropin (e.g., lipolysis) [see Clinical Pharma- cology (1.2)].
1.2 Pharmacodynamics Tissue Growth
Effects of HGH Genotropin on the tissues of the body can generally be described as anabolic (building up). Like most other protein hormones, GH acts by interacting with a specific receptor on the surface of cells. In children with GHD, the primary and most intensively studied show that action of somatropin is the stimulation of linear growth.
The measurable increase in bone length after administration of somatropin results from its effect on the cartilaginous growth areas of long bones. Studies in vitro have shown that the incorporation of sulfate into proteoglycans is not due to a direct effect of Genotropin, but rather is mediated by the somatomedins or insulin-like growth factors (IGFs). The somatomedins, among them IGF-I, are polypeptide hormones which are synthesized in the liver, kidney, and various other tissues. IGF-I levels are low in the serum of hypopituitary dwarfs and hypophysectomized humans or animals, and increase after treatment with somatropin. It is only possible when using by children!
It has been shown that the total number of skeletal muscle cells is markedly decreased in children with short stature lackin endogenous GH compared with normal children, and that treatment with somatropin results in an increase in both the number and size of muscle cells.
For prolonged high dose therapy, somatotropin influences the size of internal organs, and it also increases red cell mass.
Muscle growth is facilitated in part by increased cellular protein synthesis. This synthesis and growth are reflected by nitrogen retention which can be quantitated by observing the decline in urinary nitrogen excretion and blood urea nitrogen following the initiation of somatropin therapy.
Hypopituitary children sometimes experience fasting hypoglycemia that may be improved by treatment with Genotropin. In healthy subjects, large doses of somatropin may impair glucose tolerance.
Although the precise mechanism of the diabetogenic effect of somatotropin is not known, it is attributed to blocking the action of insulin rather than blocking insulin secretion. Insulin levels in serum actually increase as somatropin levels increase. Administration of human growth hormone to normal adults and patients with growth hormone deficiency results in increases in mean serum fasting and postprandial insulin levels, although mean values remain in the normal range. In addition, mean fasting and postprandial glucose and hemoglobin A1c levels remain in the normal range.
Somatropin stimulates intracellular lipolysis, and administration of Genotropin HGH leads to an increase in plasma free fatty acids and triglycerides. Untreated GHD is associated with increased body fat stores, including increased abdominal visceral and subcutaneous adipose tissue. Treatment of growth hormone deficient patients with somatropin results in a general reduction of fat stores, and decreased serum levels of low density lipoprotein (LDL) cholesterol.
Genotropin HGH administration results in an increase in total body potassium and phosphorus and to a lesser extent sodium. This retention is thought to be the result of cell growth. Serum levels of phosphate increase in children with GHD after somatropin therapy due to metabolic activity associated with bone growth. Serum calcium levels are not altered. Although calcium excretion in the urine is increased, there is a simultaneous increase in calcium absorption from the intestine. Negative calcium balance, however, may occasionally occur during somatropin treatment.
Connective Tissue Metabolism
HGH Genotropin stimulates the synthesis of chondroitin sulfate and collagen. In adults, this leads to: better condition of joints and tendons, improved appearance of the skin, healthier hair and nails.
Genotropin is a prescription product for the treatment of growth failure in children:
- Who do not make enough growth hormone on their own. This condition is called growth hormone deficiency (GHD).
- With a genetic condition called Prader-Willi syndrome (PWS). Growth hormone is not right for all children with PWS. Check with your doctor.
- Who were born smaller than most other babies born after the same number of weeks of preg- nancy.
- Some of these babies may not show catch-up growth by age 2 years. This condition is called small for gestational age (SGA).
- With a genetic condition called Turner syndrome (TS).
- With idiopathic short stature (ISS), which means that they are shorter than 98.8% of other children of the same age and sex; they are growing at a rate that is not likely to allow them to reach normal adult height, and their growth plates have not closed. Other causes of short height should be ruled out. ISS has no known cause.
Genotropin HGH is a prescription product for the replacement of growth hormone in adults with growth hormone deficiency (GHD) that started either in childhood or as an adult. Your doctor should do tests to be sure you have GHD, as appropriate.
Do not use Genotropin, if:
- You are allergic to any ingredient in Genotropin or in the diluent, including metacresol.
- You have active or recurring cancer or brain tumor, or you currently receive treatment for cancer.
- You have severe breathing problems (e.g., respiratory failure) or a serious illness caused by complications from a surgery or injury.
- You have a certain type of eye problem caused by diabetes (diabetic retinopathy).
- The patient is a child who has Prader-Willi syndrome and is severely overweight or has severe breathing problems (e.g., respiratory infection, history of airway blockage or sleep apnea).
- The patient is a child who has epiphyseal closure (bone growth is complete) Contact your doctor or health care provider right away if any of these apply to you.
4. Instructions for reconstitution
5. HGH Genotropin (somatropin): Side effects and Adverse reactions
This list presents the most serious and/or most frequently observed adverse reactions during treatment with somatropin:
- Sudden death in pediatric patients with Prader-Willi syndrome with risk factors including severe obesity, history of upper airway obstruction or sleep apnea and unidentified respiratory infection.
- Intracranial tumors, in particular meningiomas, in teenagers/young adults treated with radiation to the head as children for a first neoplasm and somatropin.
- Glucose intolerance including impaired glucose tolerance/impaired fasting glucose as well as overt diabetes mellitus.
- Intracranial hypertension.
- Significant diabetic retinopathy.
- Slipped capital femoral epiphysis in pediatric patients.
- Progression of pre existing scoliosis in pediatric patients.
- Fluid Retention manifested by edema, arthralgia, myalgia, nerve compression syndromes including carpal tunnel syndrome / paraesthesias.
- Unmasking of latent central hypothyroidism.
- Injection site reactions/rashes and lipoatrophy (as well as rare generalized hypersensitivity reactions).
6. Genotropin : Warnings and precautions
- Acute Critical Illness: Potential benefit of treatment continuation should be weighed against the potential risk.
- Prader-Willi Syndrome in Children: Evaluate for signs of upper airway obstruction and sleep apnea before initiation of treatment for GHD. Discontinue treatment if these signs occur.
- Neoplasm: Monitor patients with preexisting tumors for progression or recurrence. Increased risk of a second neoplasm in childhood cancer survivors treated with somatropin – in particular meningiomas in patients treated with radiation to the head for their first neoplasm.
- Impaired Glucose Tolerance and Diabetes Mellitus: May be unmasked. Periodically moni- tor glucose levels in all patients. Doses of concurrent antihyperglycemic drugs in diabetics may require adjustment.
- Intracranial Hypertension: Exclude pre existing papilledema. May develop and is usually reversible after discontinuation or dose reduction.
- Fluid Retention (i.e., edema, arthralgia, carpal tunnel syndrome – especially in adults): May occur frequently. Reduce dose as necessary.
- Hypothyroidism: May first become evident or worsen.
- Slipped Capital Femoral Epiphysis: May develop. Evaluate children with the onset of a limp or hip/knee pain.
- Progression of Pre existing Scoliosis: May develop.
- Pancreatitis: Consider pancreatitis in patients with persistent severe abdominal pain.
7. Interaction with other drugs
7.1 Inhibition of 11ί-Hydroxysteroid Dehydrogenase Type 1
The microsomal enzyme 11ί-hydroxysteroid dehydrogenase type 1 (11ίHSD-1) is required for conversion of cortisone to its active metabolite, cortisol, in hepatic and adipose tissue. GH and Genotropin inhibit 11ίHSD-1. Consequently, individuals with untreated GHD have relative increases in 11ίHSD-1 and serum cortisol. Introduction of somatotropin treatment may result in inhibition of 11ίHSD-1 and reduced serum cortisol concentrations.
As a consequence, previously undiagnosed central (secondary) hypoadrenalism may be unmasked and glucocorticoid replacement may be required in patients treated with somatropin. In addition, patients treated with glucocorticoid replacement for previously diagnosed hypoadrenalism may require an increase in their maintenance or stress doses following initiation of growth hormone treatment; this may be especially true for patients treated with cortisone acetate and prednisone since conversion of these drugs to their biologically active metabolites is dependent on the activity of 11ίHSD-1.
7.2 Pharmacologic Glucocorticoid Therapy and Supraphysiologic Glucocorticoid Treatment
Pharmacologic glucocorticoid therapy and supraphysiologic glucocorticoid treatment may attenuate the growth promoting effects of somatropin in children. Therefore, glucocorticoid replacement dosing should be carefully adjusted in children receiving concomitant Genotropin and glucocorticoid treatments to avoid both hypoadrenalism and an inhibitory effect on growth.
7.3 Cytochrome P450-Metabolized Drugs
Limited published data indicate that somatropin treatment increases cytochrome P450 (CYP450)- mediated antipyrine clearance in man. These data suggest that somatropin administration may alter the clearance of compounds known to be metabolized by CYP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, cyclosporine). Careful monitoring is advisable when growth hormone is administered in combination with other drugs known to be metabolized by CYP450 liver enzymes. However, formal drug interaction studies have not been conducted.
7.4 Oral Estrogen
Because oral estrogens may reduce the serum IGF-1 response to somatropin treatment, girls and women receiving oral estrogen replacement may require greater Genotropin dosages.
7.5 Insulin and/or Oral/Injectable Hypoglycemic Agents
In patients with diabetes mellitus requiring drug therapy, the dose of insulin and/or oral/injectable agent may require adjustment when somatotropin therapy is initiated.
8. Over dosage
Short-term over dosage could lead initially to hypoglycemia and subsequently to hyperglycemia. Furthermore, overdose with somatropin is likely to cause fluid retention.
Long-term over dosage could result in signs and symptoms of gigantism and/or acromegaly consistent with the known effects of excess growth hormone .
- This product can be used not more than 3 years from the production date (see box)
- Store in a refrigerator (2°C - 8°C). Keep in the outer carton in order to protect from light.
- In undissolved state can be stored at room temperature for one month.
Do not forget:
Genotropin is a prescription medication and should always be administered in consultation with your doctor.